chronic lymphocytic leukemia

Research in Review

CLL Long-Term Survival Likely to Improve With Novel Therapies

07/26/2017

JCP Editors

Novel agents are predicted to significantly improve lifetime overall survival (OS) and quality-adjusted life-years (QALYs) compared with traditional therapies for patients with chronic lymphocytic leukemia (CLL),...

Novel...

07/26/2017

Journal of Clinical Pathways

Research in Review

New Therapy Highly Effective in Treatment-Resistant CLL

07/18/2017

JCP Editors

A recent study reported an overall response rate (ORR) of 71% in patients with chronic lymphocytic leukemia (CLL) treated with anti-CD19 chimeric antigen receptor-modified T (CAR-T) cell therapy after prior treatment...

A...

07/18/2017

Journal of Clinical Pathways

Research in Review

CAR-T Therapy Highly Effective in Treatment-Resistant CLL

07/18/2017

JCP Editors

A...

07/18/2017

Journal of Clinical Pathways

Research in Review

Targeted Therapy Improves Survival in Older Patients With B-Cell Malignancy

06/27/2017

JCP Editors

A targeting agent is more effective in improving progression-free survival (PFS) and overall survival (OS) than conventional therapy in older patients with a treatment-naïve B-cell malignancy, according to research...

A...

06/27/2017

Journal of Clinical Pathways

Research in Review

Adding Targeted Therapy Improves CAR-T Response Rates in CLL

06/15/2017

JCP Editors

Researchers report significantly improved response rates in patients with chronic lymphocytic leukemia (CLL) treated with concurrent targeted therapy and chimeric antigen receptor T-cell (CAR-T)...

...

06/15/2017

Journal of Clinical Pathways

Research in Review

Mutations in CLL Cells May Be Used as Biomarker for Future Relapse

05/09/2017

JCP Editors

Certain mutations in relapsed chronic lymphocytic leukemia (CLL) after targeted therapy have the potential to be used as a biomarker for relapse, according to research published in the Journal of Clinical Oncology...

...

05/09/2017

Journal of Clinical Pathways

Research in Review

Older Patients With CLL Have Higher Risk of Disease-Related Mortality

05/04/2017

JCP Editors

Chronic lymphocytic leukemia (CLL)-related mortality is significantly higher in patients aged 75 years or older, prompting a need for novel treatment options, according to a study published in BMC Cancer...

...

05/04/2017

Journal of Clinical Pathways

Research in Review

Combination Therapy Improves Outcomes for Patients With CLL

03/10/2017

JCP Editors

The addition of a novel monoclonal antibody to ibrutinib significantly improves survival outcomes for patients with previously treated high-risk chronic lymphocytic leukemia (CLL), according to the results of a phase...

The...

03/10/2017

Journal of Clinical Pathways

Research in Review

Consolidation Therapy With Chemo Improves Survival for Patients With CLL

03/06/2017

JCP Editors

An intravenous consolidation regimen developed for patients with chronic lymphocytic leukemia (CLL) was found to be safe and effective, according to a report in the European Journal of...

An...

03/06/2017

Journal of Clinical Pathways

Research in Review

Genetic Mutations May Be Used as Biomarkers for Relapsing CLL

02/24/2017

JCP Editors

Mutations in the BTK and PLCG2 genes have the potential to be used as a biomarker for relapse of chronic lymphocytic leukemia (CLL) after treatment with ibrutinib, according to a retrospective review published in the...

...

02/24/2017

Journal of Clinical Pathways